Global life sciences financing entered 2026 with an apparent contradiction: fewer financing events, but substantially more capital raised. Data from Biotechgate shows that total financing reached approximately USD 65bn in H1 2026, compared with around USD 55bn in H1 2025 – an increase of roughly one-fifth. At the same time, the number of recorded financing events fell from 1,448 to 952.
The figures point to a market becoming more selective rather than simply more cautious. Capital remains available, but it is being concentrated across a smaller pool of companies and larger individual rounds. For businesses seeking funding, the message is clear: investors are still prepared to deploy significant sums, but competition for that capital remains intense.
IPOs Gather Momentum as the Half Progresses
The global life sciences IPO market produced 28 completed listings during H1 2026. Activity fluctuated considerably by month, ranging from two IPOs in January to seven in February.
More notable, however, was the movement in capital raised. June recorded only four completed IPOs but generated approximately USD 2.9bn, buoyed by Quantinuum’s listing on the Nasdaq. By comparison, February’s seven IPOs raised around USD 1bn.
Across the six months, completed life sciences IPOs raised approximately USD 7.5bn. The imbalance between transaction counts and proceeds again suggests that a small number of comparatively large offerings shaped the headline figures.
Licensing Remains a Major Source of Capital
Licensing activity was considerably more consistent. Biotechgate recorded 892 licensing deals during H1, including 184 in January and 146 in June.
Disclosed upfront payments totaled USD 9.1bn. January led the period with USD 2.7bn, followed by May at USD 1.9bn and June at USD 1.5bn. April recorded the lowest disclosed monthly total, at USD 700m.
M&A Finishes H1 on a Stronger Note
Global acquisition activity totaled 97 transactions during the period. Monthly volumes remained relatively stable through May, ranging from 13 to 17 deals, before rising to 23 acquisitions in June.
Disclosed transaction values were more volatile. March was the standout month, with approximately USD 63bn in announced deal value, followed by June at roughly USD 43bn and April at around USD 42bn. May represented the period’s low point, at approximately USD 10bn.
A Market Defined by Concentration
Taken together, the data shows an active but highly concentrated global life sciences market. Financing increased despite fewer rounds, IPO proceeds were driven by selected larger listings, and a handful of months and transactions accounted for much of the disclosed licensing and acquisition value.
More detailed market statistics and recent transactions are available through Biotechgate’s quarterly reports, spanning financing, licensing and M&A activity.